The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Large Vessel Vasculitis Outcome Measures: An Update from OMERACT

Large Vessel Vasculitis Outcome Measures: An Update from OMERACT

March 19, 2019 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“Considering the patient perspective adds further dimension to measuring disease activity,” Dr. Sreih says. “This [aspect of disease] has never been investigated in large vessel vasculitis studies, and it is an area this group has set out to explore.”

You Might Also Like
  • Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
  • New Study Aimed at Better Predicting Large Vessel Vasculitis Relapse
  • New Recommendations Guide Imaging in Large-Vessel Vasculitis
Also By This Author
  • Local Depletion of Resident Memory T Cells May Reduce Site-Specific Joint Flares

One goal of this current approach is to develop disease-specific tools that apply to large vessel vasculitis patients, given the widespread agreement that generic tools do not capture the full spectrum of large vessel vasculitis disease from patients’ perspectives.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

With this better understanding of disease states that are well-defined based on evidence in the literature, as well as data from lab findings, imaging and patient-reported outcomes and physical assessments, Dr. Sreih says this approach is “a major advancement in our understanding of large vessel vasculitis and will potentially have an impact on therapies and also the conduct of clinical trials.”

Standardized Treatment
With clinical trials being conducted based on standardized outcome measures, Dr. Aydin hopes this work will lead to new treatment approaches for large vessel vasculitis patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Because [large vessel vasculitis] has a relapsing-remitting course, physicians in clinical practice managing cases of [large vessel vasculitis] combine subjective clinical data with fairly unreliable laboratory markers and imaging to assess disease activity. On top of this [current approach], it may be very difficult to differentiate damage from active inflammation,” Dr. Aydin says.

However, with a standardized protocol for monitoring patients, when to do arterial imaging and when to change therapies, less variation in practice and clinical trials is possible.

Adding to the significance of this work, incorporating patient perspective into the outcome measures is huge for patients and an important aim of OMERACT—to include input from multiple stakeholders, Dr. Sreih says.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Carina Stanton is a freelance science journalist based in Denver.

References

  1. Aydin SZ, Robson JC, Sreih AG, et al. Update on outcome measure development in large vessel vasculitis: Report from OMERACT 2018. J Rheumatol. 2019 Mar 15. pii: jrheum.181072. doi: 10.3899/jrheum.181072. [Epub ahead of print]
  2. Direskeneli H, Aydin SZ, Kermani TA, et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: Opportunities, challenges and research agenda. J Rheumatol. 2011;38(7):1471–1479.
  3. Aydin SZ, Direskeneli H, Sreih A, et al. Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. J Rheumatol. 2015;42(12):2465–2469.
  4. Sreih AG, Alibaz-Oner F, Easley E, et al. Health-related outcomes of importance to patients with Takayasu’s arteritis. Clin Exp Rheumatol. 2018 Mar–Apr;36 Suppl 111(2):51–57. Epub 2017 Sep 18.
  5. Sreih AG, Alibaz-Oner F, Kermani TA, et al. Development of a core set of outcome measures for large-vessel vasculitis: Report from OMERACT 2016. J Rheumatol. 2017 Dec;44(12):1933–1937.
  6. Grayson PC, Alehashemi S, Bagheri AA, et al. 18 F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 2018 Mar;70(3):439–449. Epub 2018 Feb 6.
  7. Kermani TA, Diab S, Sreih AG, et al. Arterial lesions in giant cell arteritis: A longitudinal study. Semin Arthritis Rheum. 2018 May 9. pii: S0049-0172(18)30094-5. [Epub ahead of print].

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: large-vessel vasculitis, outcome, Outcome measures, Outcome Measures in Rheumatology (OMERACT), Vasculitis

You Might Also Like:
  • Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
  • New Study Aimed at Better Predicting Large Vessel Vasculitis Relapse
  • New Recommendations Guide Imaging in Large-Vessel Vasculitis
  • New Large-Vessel Vasculitis Therapies Emerge, but Better Options Still Needed

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)